194 related articles for article (PubMed ID: 15615521)
1. Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
Patel JB; Huynh CK; Handratta VD; Gediya LK; Brodie AM; Goloubeva OG; Clement OO; Nanne IP; Soprano DR; Njar VC
J Med Chem; 2004 Dec; 47(27):6716-29. PubMed ID: 15615521
[TBL] [Abstract][Full Text] [Related]
2. Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth.
Patel JB; Mehta J; Belosay A; Sabnis G; Khandelwal A; Brodie AM; Soprano DR; Njar VC
Br J Cancer; 2007 Apr; 96(8):1204-15. PubMed ID: 17387344
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effects of retinoic acid metabolism blocking agents (RAMBAs) on the growth of human prostate cancer cells and LNCaP prostate tumour xenografts in SCID mice.
Huynh CK; Brodie AM; Njar VC
Br J Cancer; 2006 Feb; 94(4):513-23. PubMed ID: 16449997
[TBL] [Abstract][Full Text] [Related]
4. Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases.
Njar VC; Gediya L; Purushottamachar P; Chopra P; Vasaitis TS; Khandelwal A; Mehta J; Huynh C; Belosay A; Patel J
Bioorg Med Chem; 2006 Jul; 14(13):4323-40. PubMed ID: 16530416
[TBL] [Abstract][Full Text] [Related]
5. Murine toxicology and pharmacokinetics of novel retinoic acid metabolism blocking agents.
Patel JB; Khandelwal A; Chopra P; Handratta VD; Njar VC
Cancer Chemother Pharmacol; 2007 Nov; 60(6):899-905. PubMed ID: 17345084
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome p450 retinoic acid 4-hydroxylase inhibitors: potential agents for cancer therapy.
Njar VC
Mini Rev Med Chem; 2002 Jun; 2(3):261-9. PubMed ID: 12370067
[TBL] [Abstract][Full Text] [Related]
7. Effects of liarozole, a new antitumoral compound, on retinoic acid-induced inhibition of cell growth and on retinoic acid metabolism in MCF-7 human breast cancer cells.
Wouters W; van Dun J; Dillen A; Coene MC; Cools W; De Coster R
Cancer Res; 1992 May; 52(10):2841-6. PubMed ID: 1581897
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of all-TRANS-retinoic acid metabolism by R116010 induces antitumour activity.
Van Heusden J; Van Ginckel R; Bruwiere H; Moelans P; Janssen B; Floren W; van der Leede BJ; van Dun J; Sanz G; Venet M; Dillen L; Van Hove C; Willemsens G; Janicot M; Wouters W
Br J Cancer; 2002 Feb; 86(4):605-11. PubMed ID: 11870544
[TBL] [Abstract][Full Text] [Related]
9. Novel therapeutic approach: organic arsenical melarsoprol) alone or with all-trans-retinoic acid markedly inhibit growth of human breast and prostate cancer cells in vitro and in vivo.
Koshiuka K; Elstner E; Williamson E; Said JW; Tada Y; Koeffler HP
Br J Cancer; 2000 Jan; 82(2):452-8. PubMed ID: 10646904
[TBL] [Abstract][Full Text] [Related]
10. Molecular recognition of CYP26A1 binding pockets and structure-activity relationship studies for design of potent and selective retinoic acid metabolism blocking agents.
Sun B; Song S; Hao CZ; Huang WX; Liu CC; Xie HL; Lin B; Cheng MS; Zhao DM
J Mol Graph Model; 2015 Mar; 56():10-9. PubMed ID: 25541526
[TBL] [Abstract][Full Text] [Related]
11. The antiproliferative activity of all-trans-retinoic acid catabolites and isomers is differentially modulated by liarozole-fumarate in MCF-7 human breast cancer cells.
Van heusden J; Wouters W; Ramaekers FC; Krekels MD; Dillen L; Borgers M; Smets G
Br J Cancer; 1998 Apr; 77(8):1229-35. PubMed ID: 9579827
[TBL] [Abstract][Full Text] [Related]
12. Novel tetralone-derived retinoic acid metabolism blocking agents: synthesis and in vitro evaluation with liver microsomal and MCF-7 CYP26A1 cell assays.
Yee SW; Jarno L; Gomaa MS; Elford C; Ooi LL; Coogan MP; McClelland R; Nicholson RI; Evans BA; Brancale A; Simons C
J Med Chem; 2005 Nov; 48(23):7123-31. PubMed ID: 16279770
[TBL] [Abstract][Full Text] [Related]
13. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
Belosay A; Brodie AM; Njar VC
Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of amide imidazole derivatives as novel metabolic enzyme CYP26A1 inhibitors.
Sun B; Liu K; Han J; Zhao LY; Su X; Lin B; Zhao DM; Cheng MS
Bioorg Med Chem; 2015 Oct; 23(20):6763-73. PubMed ID: 26365710
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and evaluation of novel mutual prodrugs (hybrid drugs) of all-trans-retinoic acid and histone deacetylase inhibitors with enhanced anticancer activities in breast and prostate cancer cells in vitro.
Gediya LK; Khandelwal A; Patel J; Belosay A; Sabnis G; Mehta J; Purushottamachar P; Njar VC
J Med Chem; 2008 Jul; 51(13):3895-904. PubMed ID: 18543902
[TBL] [Abstract][Full Text] [Related]
16. Prospective teratology of retinoic acid metabolic blocking agents (RAMBAs) and loss of CYP26 activity.
McCaffery P; Simons C
Curr Pharm Des; 2007; 13(29):3020-37. PubMed ID: 17979744
[TBL] [Abstract][Full Text] [Related]
17. Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts.
Gediya LK; Belosay A; Khandelwal A; Purushottamachar P; Njar VC
Bioorg Med Chem; 2008 Mar; 16(6):3352-60. PubMed ID: 18166465
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and CYP26A1 inhibitory activity of novel methyl 3-[4-(arylamino)phenyl]-3-(azole)-2,2-dimethylpropanoates.
Gomaa MS; Lim AS; Lau SC; Watts AM; Illingworth NA; Bridgens CE; Veal GJ; Redfern CP; Brancale A; Armstrong JL; Simons C
Bioorg Med Chem; 2012 Oct; 20(20):6080-8. PubMed ID: 22989911
[TBL] [Abstract][Full Text] [Related]
19. Molecular targeting of retinoic acid metabolism in neuroblastoma: the role of the CYP26 inhibitor R116010 in vitro and in vivo.
Armstrong JL; Taylor GA; Thomas HD; Boddy AV; Redfern CP; Veal GJ
Br J Cancer; 2007 Jun; 96(11):1675-83. PubMed ID: 17486130
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of LIAZAL, a retinoic acid metabolism blocking agent (RAMBA) with potential clinical applications in oncology and dermatology.
Freyne E; Raeymaekers A; Venet M; Sanz G; Wouters W; De Coster R; Wauwe JV
Bioorg Med Chem Lett; 1998 Feb; 8(3):267-72. PubMed ID: 9871667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
